[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-brain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,74,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100445904","wbsi-guided-personalized-delivery-of-ttfields-100445904",false,"NCT05086497","WBSI Guided Personalized Delivery of TTFields","Whole-Brain Spectroscopy Guided Personalized Mapping of Transducer Arrays for Glioblastoma Patients Receiving Tumor Treating Fields","Inclusion Criteria:\n\n* Adult population ≥ 22 years\n* Histologically confirmed diagnosis of GBM or molecular GBM according to c-IMPACT NOW criteria\n* Have undergone maximal safe surgical resection followed by either standard full course radiation of 6000 cGy in 6 weeks or a hypofractionated course of 4000 cGy in 3 weeks\n* 3 Harboring any genotype profiles (MGMT promoter methylation or unmethylation and\u002For isocitrate dehydrogenase (IDH) mutant or IDH wild-type)\n* Possessing adequate hematological, hepatic and renal functions\n* Willingness to receive TTFields\n\nExclusion Criteria:\n\n* Presence of infra-tentorial GBM\n* Pregnancy\n* Significant co-morbidities at baseline which would prevent maintenance TMZ treatment\n* Active implanted medical device, a skull defect (such as missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators,pacemakers, defibrillators and programmable shunts. , other implanted electronic devices in the brain.\n* Sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes.\n* Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality.","ALL","22 Years",{"count":19,"type":20},155,"ESTIMATED","INTERVENTIONAL",[23],"NA","This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has shown to improve overall survival in large multi-center trials. As a part of this study, participants will either receive Optune with \"standard array mapping\" (based on regular contrast enhanced MRI) or an \"alternative (more precise) array mapping\" based on sophisticated state of the art MRI techniques including \"whole brain spectroscopy\". Whole brain MRI spectroscopy provides additional metabolic information to map out the full extent of tumor spreading within the brain (far beyond from what is seen on regular MRI), by identifying certain metabolites that are present in cancer cells versus healthy tissue. This study is being performed to show whether alternative array mapping improves treatment outcomes, as opposed to the standard array mapping, by maximizing delivery of TTFields dose, thereby achieving more effective tumor cell killing, decreasing the rate of local recurrence, and improving the overall survival as well as quality of life measures.",[26,27,28],"GBM","Glioma Glioblastoma Multiforme","Tumor, Brain","RECRUITING","2026-08-05",{"date":32,"type":33},"2026-08-06","ACTUAL",{"date":35,"type":33},"2023-01-15",{"date":37,"type":20},"2027-06-30",{"name":39,"class":40},"Abramson Cancer Center at Penn Medicine","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":4,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":48,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":71,"locationsCount":4},"100514124","expanded-access-to-immunomodulatory-avm0703-for-solid-tumor-and-blood-cancer-patients-100514124","NCT05974410","Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable\u002Fchemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.",[51,52,53,54,55,56,57,58,59,60,61,62,63,28,64,65,66],"Glioblastoma","Squamous Cell Carcinoma","Hodgkin Lymphoma","Non-hodgkin Lymphoma","Breast Cancer","Prostate Cancer","Gastric Cancer","Ovarian Cancer","Acute Leukemia","Pancreatic Cancer","Spindle Cell Sarcoma","Cancer","Tumor, Solid","Esophageal Andeocarcinoma","Mixed Phenotype AML","Desmoplastic Round Cell Sarcoma","AVAILABLE","2025-09-29",{"date":70,"type":33},"2025-10-02",{"name":72,"class":73},"AVM Biotechnology Inc","INDUSTRY",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100476462","sonography-guided-resection-of-brain-mass-lesions-100476462","NCT05484245","Sonography-guided Resection of Brain Mass Lesions","Sonography-guided Resection of Brain Mass Lesions: a Prospective, Single Arm Clinical Trial","SOMALI","Inclusion Criteria:\n\n* all intracranial tumors\n* cavernomas\n* arteriovenous malformations\n* spontaneous (non-traumatic) intracerebral hemorrhages\n* traumatic intracerebral hemorrhages\n* supratentorial localization\n* newly diagnosed\n* age 18-100 years\n* stable hemodynamics\n\nExclusion Criteria:\n\n* rapid cerebral dislocation\n* previously performed brain radiotherapy","18 Years","100 Years",{"count":85,"type":20},100,[23],"Objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port.",[28,89,90,91],"Arteriovenous Malformations","Cavernoma","Intracerebral Hematoma",[93,94,95,96,97,98],"intraoperative sonography","intraoperative ultrasound","brain tumor","cavernoma","arteriovenous malformation","intracerebral hematoma","2025-05-13",{"date":101,"type":33},"2025-05-16",{"date":103,"type":33},"2022-09-01",{"date":105,"type":20},"2027-08-31",{"name":107,"class":108},"Sklifosovsky Institute of Emergency Care","OTHER_GOV",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":128,"locationsCount":109},"100475957","intraoperative-brain-shift-calculation-study-100475957","NCT05477680","Intraoperative Brain Shift Calculation Study","Intraoperative Brain Shift Calculation Study: a Prospective, Single Arm Clinical Trial","BRASH","Inclusion Criteria:\n\n* all intracranial tumors\n* cavernomas\n* arteriovenous malformations\n* spontaneous (non-traumatic) intracerebral hemorrhages\n* traumatic intracerebral hemorrhages\n* supratentorial localization\n* newly diagnosed\n* age 18-100 years\n* stable hemodynamics\n* error of patient registration in neuronavigation no more than 2 mm\n\nExclusion Criteria:\n\n* rapid cerebral dislocation",{"count":85,"type":20},[23],"The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.",[28,90,89,91],[123,124,96,97,98],"brain shift","tumor",{"date":101,"type":33},{"date":103,"type":33},{"date":105,"type":20},{"name":107,"class":108}]